Foundayo FAQ: 31 Questions About the Orforglipron Pill, Answered

Foundayo (orforglipron) is the newest GLP-1 medicine on the US market and the first small-molecule GLP-1 pill approved for weight management. It arrived in April 2026, which means most of what is written about it online is either older coverage using the name “orforglipron,” or early patient reports.

This page answers the questions people actually search, using the FDA-approved label, the published trials and Lilly’s own terms. Where it describes dosing, storage or missed doses it is summarizing the FDA-approved prescribing information and Instructions for Use — follow the directions on your own prescription and your prescriber’s instructions, which may differ. It is information, not medical advice. It never tells you what dose to take or whether to take this drug; those are conversations for a healthcare provider.

What is Foundayo?

Foundayo is the brand name for orforglipron, a once-daily tablet from Eli Lilly. The FDA approved it on April 1, 2026 [1][2].

It is a GLP-1 receptor agonist, the same broad drug family as semaglutide and tirzepatide. What makes it different is chemistry: orforglipron is a non-peptide small molecule. Semaglutide and tirzepatide are peptides, which is why they are injected, or in semaglutide’s case formulated with a special absorption enhancer to survive the stomach. Orforglipron does not need either [1].

What is Foundayo approved to treat?

The label indicates Foundayo, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition [1].

The single stated limitation of use is that taking it with another GLP-1 receptor agonist is not recommended.

What is Foundayo NOT approved for?

As of September 14, 2026, Foundayo has no FDA approval for type 2 diabetes, no approval for cardiovascular risk reduction, no approval for obstructive sleep apnea, and no pediatric indication [1]. Lilly’s second-quarter 2026 earnings release (August 5, 2026) lists the US type 2 diabetes submission among that quarter’s regulatory progress; the FDA has announced no decision [10]. Safety and effectiveness in children have not been established.

That is a meaningful gap against its nearest competitor. The Wegovy pill and injection carry an FDA-approved indication for reducing major cardiovascular events in adults with known heart disease plus obesity or overweight. Foundayo’s cardiovascular outcomes trial, ATTAIN-Outcomes, does not finish until about 2031.

How does Foundayo work?

The label says Foundayo binds to and activates the human GLP-1 receptor. GLP-1 is a natural regulator of appetite and calorie intake, and GLP-1 receptors sit in brain regions that control appetite; in animal studies orforglipron reached and activated neurons in those regions [1].

Practically, the label describes three effects: reduced body weight with more fat-mass loss than lean-mass loss, reduced food intake through decreased appetite, and delayed stomach emptying — largest after the first dose and diminishing over time [1].

Unlike tirzepatide, orforglipron acts only at the GLP-1 receptor. It has no GIP activity [1].

What doses does Foundayo come in?

Six tablet strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, each supplied in bottles of 30 with a desiccant and a child-resistant closure [1].

The label starts everyone at 0.8 mg once daily, increases to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 days, and allows further steps to 9 mg, 14.5 mg or 17.2 mg after at least 30 days at each level, based on response and tolerability. The maximum is 17.2 mg once daily [1]. Reaching the top takes at least five steps and about five months.

The ladder exists specifically to reduce gastrointestinal side effects. This is a summary of the FDA-approved label, not a schedule anyone should follow on their own; any decision about moving up or staying put belongs to a prescriber, and your prescription may differ.

Why do trial articles say 36 mg?

Because every Phase 3 trial used an investigational capsule dosed 1, 3, 6, 12, 24 and 36 mg, while the marketed product is a tablet dosed 0.8 through 17.2 mg. Lilly states the label presents trial data “shown as equivalent dosages” of the commercial tablet [1], and its 2026 press releases spell out that the 36 mg capsule corresponds to the 17.2 mg tablet.

The full mapping: 1→0.8 mg, 3→2.5 mg, 6→5.5 mg, 12→9 mg, 24→14.5 mg, 36→17.2 mg. If you are reading 2025 coverage, translate before comparing.

Do you have to take Foundayo on an empty stomach?

No. The label says take it orally once daily, with or without food [1].

This is the headline practical difference from oral semaglutide, whose label requires taking the tablet fasting, with no more than 4 ounces of plain water, and waiting at least 30 minutes before eating, drinking or taking other oral medicines.

The pharmacology backs it up. In Lilly’s food-effect study, taking orforglipron with food produced a 19% lower AUC and a 26% lower peak concentration versus fasted, with unchanged time-to-peak and half-life, and the label concludes “no clinically relevant food effect on orforglipron exposure was observed” [1]. Absolute oral bioavailability is about 77%. The acid reducer esomeprazole 40 mg had no effect on exposure [1].

Can you take Foundayo at any time of day?

The label specifies once daily and does not tie it to a clock time [1]. Because there is no food rule, people take it whenever fits their routine. If you are wondering whether a particular time is better for you, that is a question for a prescriber or pharmacist.

Can you split, crush or chew the tablets?

No. The label says tablets are swallowed whole and are not to be broken, crushed or chewed, and that no more than one tablet is taken per day [1].

How should Foundayo be stored?

At room temperature, 68 to 77 degrees Fahrenheit, with short excursions permitted between 59 and 86 degrees [1]. No refrigeration, which is one reason people cite for preferring it to injectable GLP-1 pens when traveling.

What if you miss a dose?

The label says a missed dose should be taken as soon as possible and that doses are not doubled. If seven or more consecutive doses are missed, it directs prescribers to reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal reactions, and the consumer materials direct patients to their provider about restarting [1][3].

Orforglipron’s elimination half-life is roughly 29 to 49 hours, so a single missed day produces a smaller swing in blood levels than missing a weekly injection [1]. That is context, not permission. What to do about a specific missed dose is a question for your prescriber or pharmacist, and your own prescription governs.

What are the most common side effects?

From the pooled ATTAIN-1 and ATTAIN-2 data in the label, at the three doses studied versus placebo [1]: nausea 26–35% versus 10%, constipation 20–27% versus 9%, diarrhea 21–25% versus 11%, vomiting 13–24% versus 4%, indigestion 12–16% versus 4%, stomach pain 13–14% versus 7%, fatigue 6–9% versus 4%, hair loss 4–5% versus 2%.

Gastrointestinal reactions of any kind occurred in 60% to 69% of people on Foundayo versus 37% on placebo, and among those who had them, 60% were mild, 36% moderate and 4% severe [1]. Eight percent of people stopped Foundayo permanently because of adverse reactions versus 3% on placebo.

Does Foundayo have a boxed warning?

Yes, the GLP-1 class warning about thyroid C-cell tumors seen in rodents. Foundayo is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1].

Foundayo’s version has a twist: the label states orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. The FDA applied the class warning anyway because the drug does activate the human receptor, saying the human relevance of the rodent finding has not been determined [1].

Does Foundayo affect birth control pills?

The label advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method, for 30 days after initiation of Foundayo and for 30 days after each dose escalation. Hormonal contraceptives not administered orally should not be affected [1][2]. The reason given is delayed gastric emptying, which may affect absorption of oral medicines. The label notes this effect has not actually been tested in a clinical trial.

Because Foundayo has five dose steps above the starting dose, someone titrating to the maximum could face several separate 30-day windows.

What other drugs interact with Foundayo?

More than you might expect, because orforglipron is broken down by the liver enzyme CYP3A4 [1]:

• With a strong CYP3A4 inhibitor, the label caps Foundayo at 9 mg daily. Clarithromycin raised exposure 3.5-fold.
• OATP1B inhibitors: cyclosporine raised exposure 2.6-fold. The label says to avoid strong CYP3A4 inhibitors that also inhibit OATP1B, naming ritonavir.
• Strong CYP3A4 inducers: avoid. Carbamazepine cut exposure 82%.
• Simvastatin: capped at 20 mg daily, because Foundayo doubled simvastatin acid exposure.

Because Foundayo slows stomach emptying, it can affect absorption of oral medicines in general. Give your pharmacist your full medication list.

Can you take Foundayo with kidney or liver problems?

The label says no dose change is recommended for any degree of kidney impairment, including end-stage renal disease, because renal impairment does not change orforglipron’s pharmacokinetics. Only about 1% of a dose leaves in urine and 87% in feces [1].

Liver is the opposite. Exposure rose 1.7-fold in moderate and 4.6-fold in severe hepatic impairment, and Foundayo is not recommended in severe hepatic impairment (Child-Pugh C) [1].

Can you take Foundayo while pregnant or breastfeeding?

The label states that weight loss offers no benefit during pregnancy and may cause fetal harm, and directs that Foundayo be discontinued when pregnancy is recognized. It is not recommended for nursing women; orforglipron passed into rat milk at three times plasma concentrations [1]. A pregnancy exposure registry is being established.

What about surgery or anesthesia?

The label addresses pulmonary aspiration during anesthesia or deep sedation and says available data are insufficient to recommend modifying fasting rules or pausing the drug before procedures. It instructs patients to tell their care team they are taking it [1].

How much weight do people lose on Foundayo?

In ATTAIN-1, the pivotal 72-week trial in 3,127 adults, the top 17.2 mg dose produced an average loss of 27.3 pounds (12.4%) among people who stayed on treatment — the efficacy estimand — versus 2.2 pounds (0.9%) on placebo. Counting everyone regardless of whether they stopped, the New England Journal of Medicine reported 11.2%, roughly 25 pounds, against 2.1%. The FDA label’s intent-to-treat analysis prints 11.1% versus 2.1% [1][4].

At the top dose on the efficacy estimand, 77.1% lost at least 5%, 59.6% lost at least 10%, 39.6% lost at least 15% and 20.1% lost at least 20% [4]. The label’s intent-to-treat table is more conservative: 71.5%, 54.5%, 35.9% and 18.4%, against 26.8%, 13%, 6% and 2.9% on placebo [1].

How long does it take to work?

ATTAIN-1’s primary endpoint was measured at 72 weeks, roughly 17 months. The dose ladder alone takes at least five months to complete. Individual timelines vary widely, and the trial averages are not a prediction for any one person.

Does Foundayo work as well as Zepbound or Wegovy?

There is no head-to-head trial against either injectable. Across separate trials with different designs and populations, Zepbound produced about 20.2% and injectable Wegovy about 13.7% average weight loss over 72 weeks in SURMOUNT-5, against 12.4% for Foundayo’s top dose in ATTAIN-1. That is a rough signal, not a measurement.

Against the other GLP-1 pill, Foundayo won the only head-to-head trial that exists, ACHIEVE-3 — but that trial was in people with type 2 diabetes and used oral semaglutide’s 7 mg and 14 mg diabetes doses, not the 25 mg Wegovy weight-management tablet.

Can you switch from an injection to Foundayo?

That is a prescriber decision. What the evidence shows: ATTAIN-MAINTAIN randomized 376 people who had plateaued on maximum-tolerated Wegovy or Zepbound and started them on the 9 mg tablet-equivalent dose. After a year, those coming from Wegovy kept all but about 2 pounds of their prior weight loss and those from Zepbound kept all but about 11 pounds — described in summaries of the paper as retaining roughly 75% to 82% of it, against roughly 38% to 49% on placebo [5].

Two things that trial does not answer: whether starting a switcher at 0.8 mg gives the same result, and how switching compares with simply staying on the injectable. Lilly’s own consumer FAQ declines to name a starting dose for switchers and routes the question to a doctor [3].

How much does Foundayo cost?

Lilly’s published self-pay ladder is $149 a month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg (verified 2026-09-14) — with the 2.5 mg dose temporarily at $149 and 5.5 mg temporarily at $199 through December 31, 2026, and the top two doses at $299 under a refill-within-45-days program [6]. Those are point prices per dose, not a range.

With commercial insurance that covers Foundayo, Lilly’s savings card can bring the cost to as little as $25 a month, capped at $100 per one-month fill and $1,000 per year, expiring December 31, 2026 [6]. That $25 is a savings-card tier that requires your plan to cover the drug, not a cash price. Without any savings program, Lilly’s published list price (wholesale acquisition cost) is $649 for a 30-day supply at every strength [12], and GoodRx reports retail cash prices of $739.80 to $788.68 for 30 tablets [13].

Does insurance cover Foundayo?

Increasingly. All three of the largest pharmacy benefit managers agreed in May 2026 to cover Lilly’s obesity portfolio, and CVS Caremark added Foundayo to its commercial templates on June 1, 2026. Plenty of employer plans still exclude weight-management drugs or require prior authorization. Call the number on your insurance card and ask specifically about GLP-1 coverage for obesity.

Does Medicare cover Foundayo?

Not through regular Part D, which is barred by law from covering weight-loss drugs. CMS opened the Medicare GLP-1 Bridge on July 1, 2026, a demonstration covering Foundayo and several other obesity drugs at a flat $50 monthly copay for eligible beneficiaries through December 31, 2027 [7]. The $50 does not count toward your deductible or out-of-pocket cap and is not reduced by Extra Help.

Lilly’s commercial savings card cannot be used by anyone in Medicare, Medicaid, TRICARE, VA or a state drug assistance program [6].

Where do you get Foundayo?

LillyDirect is the channel Lilly promotes, with savings applied automatically and free home shipping through contracted pharmacies including Amazon Pharmacy, Fuze Health, Gifthealth and Walmart Pharmacy [3]. LillyDirect is owned by Eli Lilly and dispenses only Lilly products, so it is a manufacturer channel rather than a neutral comparison.

The same self-pay price is available at retail pharmacies through Lilly’s Other Pharmacy route, and patients have documented filling at Costco and CVS at the published prices. Several telehealth services also write for Foundayo, usually with their own membership or visit fees on top of the drug price.

Is there a generic or a compounded version?

No generic. Foundayo was approved in April 2026 and is sold only as a Lilly brand product.

On compounding: Lilly has said since 2025 that it expects to launch orforglipron worldwide without supply constraints, because a small molecule is made by conventional synthesis rather than the specialized peptide capacity that limited semaglutide and tirzepatide supply in 2023 and 2024. The FDA has not approved any compounded version of orforglipron, and compounded formulations are not evaluated by the agency for safety, purity or potency. Any offer of “compounded orforglipron” is worth raising with a pharmacist or prescriber.

Is Foundayo available outside the US?

The UK’s MHRA authorized orforglipron on August 10, 2026 for both weight management and type 2 diabetes, and it went on sale in UK pharmacies on private prescription on August 24, 2026, making the UK the first country in Europe to roll it out. Lilly has filed in multiple other markets. Availability, pricing and reimbursement differ by country.

Who discovered orforglipron?

Chugai Pharmaceutical Co., Ltd. of Japan. Eli Lilly licensed it in 2018, and the two companies co-published how the molecule activates the human GLP-1 receptor in 2020 [2].

What do patients say about it?

On Drugs.com, Foundayo carried a 7.0 out of 10 average from 40 reviews, with 50% reporting a positive experience and 13% negative, and nausea, constipation and fatigue named as the most commonly mentioned side effects [8]. That figure is carried forward from an earlier check rather than re-verified on September 14, 2026, because Drugs.com blocks automated retrieval; treat it as approximate.

Across the Foundayo communities on Reddit, the most-cited benefits are no needles, no refrigeration and no timing rules. The most-cited complaints are constipation, which people who have used injectables often describe as worse on the pill, and fatigue in the first weeks. People restarted near the bottom of the dose ladder after coming off high-dose tirzepatide frequently report hunger returning during titration.

All of that is anecdote from self-selected posters. It is useful for knowing what to ask about. It is not evidence of how well the drug works.

What is still unknown about Foundayo?

The honest list, as of September 14, 2026:

• No cardiovascular outcomes data until roughly 2031.
• No randomized comparison against injectable GLP-1s, or against the 25 mg Wegovy tablet in people without diabetes.
• No published real-world study; the drug has been on the market about five months.
• No pediatric or adolescent data yet.
• FDA postmarketing requirements attached at approval, covering unexpected major adverse cardiovascular events, drug-induced liver injury, retained gastric contents and exposure during lactation, are still being worked through [9]. ACHIEVE-4 reported no hepatic safety signal in April 2026, but the formal program continues.
• No US type 2 diabetes approval yet.

Sources

1. FOUNDAYO (orforglipron) tablets, US Prescribing Information, revised 7/2026 — Eli Lilly and Company
2. FDA Approves Lilly’s Foundayo (orforglipron) — Eli Lilly, April 1, 2026
3. LillyDirect: Foundayo — Eli Lilly and Company
4. ATTAIN-1 topline results — Eli Lilly, August 7, 2025
5. ATTAIN-MAINTAIN results — Nature Medicine, May 2026
6. Foundayo coverage and savings terms — Eli Lilly and Company
7. Medicare GLP-1 Bridge — Centers for Medicare & Medicaid Services
8. Foundayo user reviews — Drugs.com
9. NDA 220934 approval letter, Foundayo (orforglipron) tablets — US Food and Drug Administration, signed April 1, 2026, posted April 14, 2026
10. Lilly reports second-quarter 2026 financial results — Eli Lilly and Company, August 5, 2026
11. ACHIEVE-3 head-to-head results — The Lancet, February 26, 2026
12. Foundayo cost information: list price (WAC) — Lilly Pricing Info, Eli Lilly and Company
13. Foundayo prices and coupons — GoodRx